Quick takeaway
Post-launch study evidence in India older adults aged 65+ focused on influenza vaccination and tracked safety and reactogenicity. Adds elder-specific post-approval vaccine safety evidence in the Indian context.
Why this matters
Adds elder-specific post-approval vaccine safety evidence in the Indian context.
Key caution
The result is useful for decision support, but design and setting should still be checked before broad rollout.